In part 4 of this Exclusive Interview, Lisa Latts talks with Diabetes in Control Publisher Steve Freed about the genesis of Watson and the work currently in the pipeline.
Lisa Latts MD, MSPH, MBA, FACP is Deputy Chief Health Officer for IBM Watson Health.
Transcript of this video segment:
Freed: How long has Watson been around?
Latts: So, Watson the artificial intelligence computer was launched with Jeopardy — do you remember the Jeopardy? Yeah, so it was launched with the Jeopardy game. Watson Health as a separate entity was April, three years ago. So, Watson Health, the organization, is about three and a couple months old.
Freed: Are you presenting any other lesson or information here at ADA?
Latts: Yeah. Thanks for asking. So, we’ve got the Guardian Connect, Sugar.IQ, and we’ve got an analytic study that I presented yesterday looking at adherence for individuals with diabetes. We’ve also got a poster that uses machine learning to look at how different classes of diabetes drugs affect cardiovascular outcomes. So, looking at acute myocardial infarction, looking at congestive heart failure, looking at stroke, so looking at those outcomes by different classes of diabetes drugs. And then we’ve also got a proof of concept that we’re doing with the American Diabetes Association as part of this partnership where we are looking at, “Can Watson help make available to researchers and physicians all of this amazing information that’s being delivered in a video format but that is incredibly difficult to find?” So, if you’re a scientist and you’re like, “When I was at the ADA last summer, I know that someone was talking about the effect of heavy metals in diabetes but I can’t remember what it was.” So, the idea behind this proof of concept is that you would ask the question in Watson and it would pop up not just the correct video but actually the clip within the video where they answer that question. So, we’ve tested a proof of concept based on ingesting 90 hours of video. And now we’ve done some preliminary testing. We’ve got very favorable opinions and we’re continuing to improve and continuing to build. And so, now we’ll be looking at developing a beta test and then looking at developing some sponsorship for this app to make it available for scientists and other researchers.